{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T04:49:52Z","timestamp":1697345392676},"reference-count":68,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.cld.2009.05.012","type":"journal-article","created":{"date-parts":[[2009,7,22]],"date-time":"2009-07-22T09:19:43Z","timestamp":1248254383000},"page":"487-501","source":"Crossref","is-referenced-by-count":11,"title":["Thrombopoietin Agonists for the Treatment of Thrombocytopenia in Liver Disease and Hepatitis C"],"prefix":"10.1016","volume":"13","author":[{"given":"Geoffrey","family":"Dusheiko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.cld.2009.05.012_bib1","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jhep.2008.03.009","article-title":"Thrombocytopenia associated with chronic liver disease","volume":"48","author":"Afdhal","year":"2008","journal-title":"J Hepatol"},{"issue":"4 Suppl 5","key":"10.1016\/j.cld.2009.05.012_bib2","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.seminhematol.2007.11.003","article-title":"Current options for the treatment of idiopathic thrombocytopenic purpura","volume":"44","author":"Arnold","year":"2007","journal-title":"Semin Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2009.05.012_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2036.2007.03510.x","article-title":"Review article: thrombocytopenia in chronic liver disease","volume":"26","author":"Poordad","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.cld.2009.05.012_bib4","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/hep.21303","article-title":"Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management","volume":"44","author":"Caldwell","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2009.05.012_bib5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/hep.21266","article-title":"Thrombin generation in patients with cirrhosis: the role of platelets","volume":"1944","author":"Tripodi","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2009.05.012_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11894-009-0002-x","article-title":"Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C","volume":"11","author":"Tillmann","year":"2009","journal-title":"Curr Gastroenterol Rep"},{"issue":"6","key":"10.1016\/j.cld.2009.05.012_bib7","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/j.1365-2141.2005.05542.x","article-title":"Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura","volume":"129","author":"Rajan","year":"2005","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.cld.2009.05.012_bib8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s11938-007-0046-7","article-title":"Coagulopathy in liver disease","volume":"10","author":"Blonski","year":"2007","journal-title":"Curr Treat Options Gastroenterol"},{"issue":"8","key":"10.1016\/j.cld.2009.05.012_bib9","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/j.1365-2036.2006.02889.x","article-title":"Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options","volume":"23","author":"Giannini","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2009.05.012_bib10","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1665-2681(19)31854-X","article-title":"Thrombopoietin level in patients with chronic liver diseases","volume":"7","author":"Eissa","year":"2008","journal-title":"Ann Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2009.05.012_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOH.0b013e32830a9746","article-title":"Thrombocytopenia in liver disease","volume":"15","author":"Giannini","year":"2008","journal-title":"Curr Opin Hematol"},{"issue":"3","key":"10.1016\/j.cld.2009.05.012_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/ajh.2830500305","article-title":"Platelet autoantibodies in patients with chronic liver disease","volume":"50","author":"Pereira","year":"1995","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.cld.2009.05.012_bib13","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1111\/j.1572-0241.2002.05845.x","article-title":"Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection","volume":"97","author":"Pockros","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.cld.2009.05.012_bib14","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1365-2036.2008.03674.x","article-title":"Review article: blood platelet number and function in chronic liver disease and cirrhosis","volume":"27","author":"Witters","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cld.2009.05.012_bib15","article-title":"Platelets contribute to the reduction of liver fibrosis in mice","author":"Watanabe","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2009.05.012_bib16","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/hep.21440","article-title":"Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: lessons from the HALT-C trial","volume":"44","author":"Everson","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2009.05.012_bib17","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood-2007-12-125906","article-title":"Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes","volume":"112","author":"Yamane","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cld.2009.05.012_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.7326\/0003-4819-127-4-199708150-00005","article-title":"Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation","volume":"127","author":"Martin","year":"1997","journal-title":"Ann Intern Med"},{"issue":"Suppl D","key":"10.1016\/j.cld.2009.05.012_bib19","doi-asserted-by":"crossref","first-page":"60D","DOI":"10.1155\/2000\/617428","article-title":"Thrombocytopenia in liver disease","volume":"14","author":"Peck-Radosavljevic","year":"2000","journal-title":"Can J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2009.05.012_bib20","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood.V95.3.795.003k25_795_801","article-title":"Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production","volume":"95","author":"Peck-Radosavljevic","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.cld.2009.05.012_bib21","article-title":"Thrombopoietin and thrombopoietin mimetics in the treatment of thrombocytopenia","author":"Kuter","year":"2008","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.cld.2009.05.012_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0609.2007.00999.x","article-title":"New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura","volume":"69","author":"Kuter","year":"2008","journal-title":"Eur J Haematol Suppl"},{"issue":"Suppl D","key":"10.1016\/j.cld.2009.05.012_bib23","doi-asserted-by":"crossref","first-page":"73D","DOI":"10.1155\/2000\/681394","article-title":"Clinical biology and potential use of thrombopoietin","volume":"14","author":"Basser","year":"2000","journal-title":"Can J Gastroenterol"},{"issue":"9","key":"10.1016\/j.cld.2009.05.012_bib24","first-page":"716","volume":"30","author":"Xu","year":"2008","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"5","key":"10.1016\/j.cld.2009.05.012_bib25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/1381612023395989","article-title":"The impact of thrombopoietin on clinical practice","volume":"8","author":"Basser","year":"2002","journal-title":"Curr Pharm Des"},{"issue":"2","key":"10.1016\/j.cld.2009.05.012_bib26","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000125192","article-title":"Interleukin-11 for treatment of hepatitis C-associated ITP","volume":"119","author":"Fontana","year":"2008","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1016\/j.cld.2009.05.012_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1055\/s-0037-1616946","article-title":"Chronic immune thrombocytopenic purpura. New agents","volume":"29","author":"Rodeghiero","year":"2009","journal-title":"Hamostaseologie"},{"issue":"9610","key":"10.1016\/j.cld.2009.05.012_bib28","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"issue":"5319","key":"10.1016\/j.cld.2009.05.012_bib29","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1126\/science.276.5319.1696","article-title":"Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine","volume":"276","author":"Cwirla","year":"1997","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.cld.2009.05.012_bib30","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2165\/00003495-200868070-00002","article-title":"Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura","volume":"68","author":"Stasi","year":"2008","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.cld.2009.05.012_bib31","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","article-title":"Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand","volume":"76","author":"Wang","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.cld.2009.05.012_bib32","first-page":"608","volume":"43","author":"Zhao","year":"2004","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"11","key":"10.1016\/j.cld.2009.05.012_bib33","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1182\/blood-2006-11-057968","article-title":"Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist","volume":"109","author":"Jenkins","year":"2007","journal-title":"Blood"},{"issue":"1\u20133","key":"10.1016\/j.cld.2009.05.012_bib34","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ejphar.2008.02.060","article-title":"Characterization of novel non-peptide thrombopoietin mimetics, their species specificity and the activation mechanism of the thrombopoietin receptor","volume":"586","author":"Yamane","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cld.2009.05.012_bib35","article-title":"Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietin receptor agonist","author":"Erickson-Miller","year":"2008","journal-title":"Stem Cells"},{"issue":"6","key":"10.1016\/j.cld.2009.05.012_bib36","first-page":"344","article-title":"Molecule of the month. Eltrombopag","volume":"21","year":"2008","journal-title":"Drug News Perspect"},{"issue":"22","key":"10.1016\/j.cld.2009.05.012_bib37","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa073275","article-title":"Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura","volume":"357","author":"Bussel","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.cld.2009.05.012_bib38","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1056\/NEJMc073571","article-title":"Eltrombopag in thrombocytopenia","volume":"358","author":"Lawson","year":"2008","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.cld.2009.05.012_bib39","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMoa073255","article-title":"Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C","volume":"357","author":"McHutchison","year":"2007","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.cld.2009.05.012_bib40","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1016\/j.bmcl.2008.08.068","article-title":"Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor","volume":"18","author":"Alper","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"issue":"19","key":"10.1016\/j.cld.2009.05.012_bib41","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1016\/j.bmcl.2008.08.077","article-title":"Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold","volume":"18","author":"Marsilje","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"issue":"10","key":"10.1016\/j.cld.2009.05.012_bib42","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3324\/haematol.12752","article-title":"The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis","volume":"93","author":"Nogami","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.cld.2009.05.012_bib43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1042\/BSR20080086","article-title":"Discovery of novel non-peptide thrombopoietin mimetic compounds that induce megakaryocytopoiesis","volume":"28","author":"Yamane","year":"2008","journal-title":"Biosci Rep"},{"issue":"10","key":"10.1016\/j.cld.2009.05.012_bib44","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.exphem.2008.04.020","article-title":"AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis","volume":"36","author":"Fukushima-Shintani","year":"2008","journal-title":"Exp Hematol"},{"issue":"4","key":"10.1016\/j.cld.2009.05.012_bib45","first-page":"257","volume":"49","author":"Nakamura","year":"2008","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.cld.2009.05.012_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/clpt.2008.96","article-title":"Pharmacodynamics and pharmacokinetics of the novel thrombopoietin mimetic peptide RWJ-800088 in humans","author":"Liem-Moolenaar","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cld.2009.05.012_bib47","doi-asserted-by":"crossref","DOI":"10.1634\/theoncologist.2008-0132","article-title":"Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis","author":"Gernsheimer","year":"2009","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.cld.2009.05.012_bib48","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0908-917","article-title":"Boosting platelet production","volume":"14","author":"Wei","year":"2008","journal-title":"Nat Med"},{"issue":"4 Suppl 5","key":"10.1016\/j.cld.2009.05.012_bib49","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.seminhematol.2007.11.005","article-title":"Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura","volume":"44","author":"Newland","year":"2007","journal-title":"Semin Hematol"},{"issue":"2 Suppl 2","key":"10.1016\/j.cld.2009.05.012_bib50","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2146\/ajhp080490","article-title":"Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura","volume":"66","author":"Pruemer","year":"2009","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.cld.2009.05.012_bib51","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2141.2008.07275.x","article-title":"Refractory immune thrombocytopenic purpura: current strategies for investigation and management","volume":"143","author":"Psaila","year":"2008","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.cld.2009.05.012_bib52","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1056\/NEJMe0707126","article-title":"Immune thrombocytopenic purpura\u2014from agony to agonist","volume":"357","author":"Schwartz","year":"2007","journal-title":"N Engl J Med"},{"issue":"5177","key":"10.1016\/j.cld.2009.05.012_bib53","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1126\/science.8073287","article-title":"Thrombocytopenia in c-mpl-deficient mice","volume":"265","author":"Gurney","year":"1994","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.cld.2009.05.012_bib54","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJM200012073432302","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis","volume":"343","author":"Heathcote","year":"2000","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.cld.2009.05.012_bib55","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/00004836-200609000-00015","article-title":"Splenectomy for thrombocytopenia in patients with hepatitis C cirrhosis","volume":"40","author":"Hayashi","year":"2006","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2009.05.012_bib56","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00042737-200601000-00023","article-title":"Proximal splenic artery embolization allows pegylated interferon and ribavirin combination therapy in chronic hepatitis C virus-infected patients with severe cytopenia","volume":"18","author":"Annicchiarico","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2009.05.012_bib57","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1097\/01.TP.0000155424.52939.3D","article-title":"Partial splenic embolization for the treatment of hypersplenism in liver transplanted patients with hepatitis C virus recurrence before peg-interferon plus ribavirin","volume":"79","author":"Barcena","year":"2005","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.cld.2009.05.012_bib58","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s00535-005-1693-x","article-title":"Partial splenic embolization facilitates completion of interferon therapy in patients with chronic HCV infection and hypersplenism","volume":"40","author":"Kato","year":"2005","journal-title":"J Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2009.05.012_bib59","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1177\/135965350400900605","article-title":"Partial splenic embolization for the treatment of hypersplenism in cirrhotic HIV\/HCV patients prior to pegylated interferon and ribavirin","volume":"9","author":"Moreno","year":"2004","journal-title":"Antivir Ther"},{"issue":"11","key":"10.1016\/j.cld.2009.05.012_bib60","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/00042737-200511000-00001","article-title":"Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection","volume":"17","author":"Palsson","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2009.05.012_bib61","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1432-2277.2006.00263.x","article-title":"The use of partial splenic artery embolization made it possible to administer interferon and ribavirin therapy in a liver transplant patient with fibrosing cholestatic hepatitis C complicated with thrombocytopenia","volume":"19","author":"Sohara","year":"2006","journal-title":"Transpl Int"},{"issue":"7","key":"10.1016\/j.cld.2009.05.012_bib62","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/QAD.0b013e3280d64a0a","article-title":"Partial splenic embolization as a treatment for hypersplenism in HIV\/hepatitis C virus-co-infected patients","volume":"21","author":"Unzurrunzaga","year":"2007","journal-title":"AIDS"},{"issue":"Suppl 1","key":"10.1016\/j.cld.2009.05.012_bib63","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2036.2007.03511.x","article-title":"Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection","volume":"26","author":"Afdhal","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.cld.2009.05.012_bib64","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/09537100701593601","article-title":"Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders","volume":"18","author":"Ceresa","year":"2007","journal-title":"Platelets"},{"issue":"3","key":"10.1016\/j.cld.2009.05.012_bib65","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2007-05-088500","article-title":"Historical review: megakaryopoiesis and thrombopoiesis","volume":"111","author":"Kaushansky","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cld.2009.05.012_bib66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1600-0609.2007.01001.x","article-title":"Emerging strategies to treat chronic immune thrombocytopenic purpura","volume":"69","author":"Newland","year":"2008","journal-title":"Eur J Haematol Suppl"},{"key":"10.1016\/j.cld.2009.05.012_bib67","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1600-0609.2007.01000.x","article-title":"First-line therapies for immune thrombocytopenic purpura: re-evaluating the need to treat","volume":"69","author":"Rodeghiero","year":"2008","journal-title":"Eur J Haematol Suppl"},{"issue":"10","key":"10.1016\/j.cld.2009.05.012_bib68","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1056\/NEJMc073571","article-title":"Eltrombopag in thrombocytopenia","volume":"358","author":"Zimmer","year":"2008","journal-title":"N Engl J Med"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326109000385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326109000385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T03:03:26Z","timestamp":1685070206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326109000385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S1089326109000385"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2009.05.012","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}